|
JPS5992710A
(ja)
*
|
1982-11-16 |
1984-05-29 |
関西電力株式会社 |
直接水冷線路の立坑部の布設方法
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
CA2559228C
(en)
|
2004-04-21 |
2016-06-21 |
Enobia Pharma Inc. |
Bone delivery conjugates and method of using same to target proteins to bone
|
|
RU2423381C2
(ru)
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
GB0614780D0
(en)
*
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
CA2680792A1
(en)
*
|
2007-03-15 |
2008-09-18 |
Biogen Idec Ma Inc. |
Treatment of autoimmune disorders
|
|
PL2185589T3
(pl)
|
2007-06-01 |
2016-09-30 |
|
Środki wiążące receptor regionu stałego Fc immunoglobuliny
|
|
JP2010532764A
(ja)
*
|
2007-07-06 |
2010-10-14 |
トゥルビオン・ファーマシューティカルズ・インコーポレーテッド |
Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
US20090148905A1
(en)
*
|
2007-11-30 |
2009-06-11 |
Claire Ashman |
Antigen-binding constructs
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
US20110263484A1
(en)
*
|
2008-10-13 |
2011-10-27 |
Zymogenetics, Inc. |
Single chain fc type iii interferons and methods of using same
|
|
WO2010065578A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Leukosight Inc. |
POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
|
|
ES2410579T5
(es)
|
2008-12-16 |
2021-10-04 |
Novartis Ag |
Sistemas de despliegue de levaduras
|
|
ES2712732T3
(es)
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
|
EP2478013B1
(en)
|
2009-09-16 |
2018-10-24 |
F.Hoffmann-La Roche Ag |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
AU2010306774A1
(en)
*
|
2009-10-14 |
2012-05-03 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
|
|
TW201120210A
(en)
*
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
|
AU2010325969B2
(en)
*
|
2009-12-02 |
2016-10-20 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
|
|
EP2517555A4
(en)
|
2009-12-25 |
2014-09-24 |
Chugai Pharmaceutical Co Ltd |
SEARCHING AND SCREENING METHOD FOR A TARGET MOLECULE OF A CANCER WITH A NON-MENTAL ANIMAL MODEL WITH A NO-CANCER LINE OF TRANSPLANTED LINE
|
|
SG10201503351RA
(en)
|
2010-01-19 |
2015-06-29 |
Harvard College |
Engineered Opsonin for Pathogen Detection and Treatment
|
|
EP2533811A4
(en)
*
|
2010-02-12 |
2013-12-25 |
Res Corp Technologies Inc |
MULTIMETER PROTEINS WITH IMMUNE LOBULIN CONSTANTS DOMAINS
|
|
ES2717883T3
(es)
*
|
2010-03-25 |
2019-06-26 |
Ucb Biopharma Sprl |
Moléculas de DVD-LG estabilizadas con disulfuro
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
HRP20171045T1
(hr)
|
2010-04-16 |
2017-10-06 |
Biogen Ma Inc. |
Protutijela anti-vla-4
|
|
TW201217527A
(en)
|
2010-07-09 |
2012-05-01 |
Biogen Idec Hemophilia Inc |
Processable single chain molecules and polypeptides made using same
|
|
TWI542597B
(zh)
|
2010-07-28 |
2016-07-21 |
吉林尼克公司 |
產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
JP6230789B2
(ja)
|
2010-10-06 |
2017-11-15 |
中外製薬株式会社 |
癌幹細胞集団及びその作製方法
|
|
US9518132B2
(en)
|
2010-11-09 |
2016-12-13 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012088608A1
(en)
|
2010-12-27 |
2012-07-05 |
Enobia Canada Limited Partnership |
Compositions comprising natriuretic peptides and methods of use thereof
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2013012733A1
(en)
*
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
AU2012284097B2
(en)
|
2011-07-18 |
2017-08-03 |
President And Fellows Of Harvard College |
Engineered microbe-targeting molecules and uses thereof
|
|
JP5987057B2
(ja)
*
|
2011-07-27 |
2016-09-06 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
|
|
BR112014003315A2
(pt)
|
2011-08-15 |
2017-03-01 |
Univ Chicago |
composições e métodos relacionados a anticorpos para a proteína a estafilocócica
|
|
PE20141522A1
(es)
|
2011-08-17 |
2014-11-17 |
Glaxo Group Ltd |
Proteinas y peptidos modificados
|
|
CA2843158A1
(en)
*
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
EP2749641B1
(en)
|
2011-09-07 |
2021-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
HUE034044T2
(en)
|
2011-09-30 |
2018-01-29 |
Dana Farber Cancer Inst Inc |
Therapeutic peptides
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
RU2654567C2
(ru)
*
|
2011-10-11 |
2018-05-21 |
Дженентек, Инк. |
Улучшенная сборка биспецифических антител
|
|
EP2772268B8
(en)
|
2011-10-28 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR20230143201A
(ko)
|
2011-11-30 |
2023-10-11 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
WO2013096346A1
(en)
*
|
2011-12-22 |
2013-06-27 |
Development Center For Biotechnology |
Bispecific t-cell activator antibody
|
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
|
US9676849B2
(en)
*
|
2012-01-10 |
2017-06-13 |
Biogen Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
CA2861124A1
(en)
*
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
USRE49477E1
(en)
|
2012-04-20 |
2023-03-28 |
Thomas Jefferson University |
Engineered antibody for inhibition of fibrosis
|
|
US9969794B2
(en)
|
2012-05-10 |
2018-05-15 |
Visterra, Inc. |
HA binding agents
|
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
WO2013185010A1
(en)
*
|
2012-06-07 |
2013-12-12 |
Duke University |
HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
|
|
WO2013185113A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
|
CA2875247A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
US9926365B2
(en)
*
|
2012-06-29 |
2018-03-27 |
Bristol-Myers Squibb Company |
Methods for reducing glycoprotein aggregation
|
|
MY175687A
(en)
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
US9683044B2
(en)
*
|
2012-08-20 |
2017-06-20 |
Gliknik Inc. |
Molecules with antigen binding and polyvalent FC gamma receptor binding activity
|
|
JO3462B1
(ar)
*
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
SG10201709559PA
(en)
|
2012-08-24 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
|
BR112015008663B1
(pt)
*
|
2012-10-17 |
2021-01-12 |
CSL Behring Lengnau AG |
Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
|
|
WO2014083379A1
(en)
*
|
2012-11-30 |
2014-06-05 |
Institut Pasteur |
Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
|
|
US10487155B2
(en)
*
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102211837B1
(ko)
*
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
WO2014126871A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
|
WO2014127215A1
(en)
|
2013-02-15 |
2014-08-21 |
Biogen Idec Ma Inc. |
Optimized factor viii gene
|
|
HK1220465A1
(zh)
*
|
2013-03-06 |
2017-05-05 |
Merrimack Pharmaceuticals, Inc. |
抗c-met串联fc双特异性抗体
|
|
SG11201506766PA
(en)
|
2013-03-15 |
2015-09-29 |
Dana Farber Cancer Inst Inc |
Therapeutic peptides
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US9352020B2
(en)
|
2013-03-15 |
2016-05-31 |
Mead Johnson Nutrition Company |
Reducing proinflammatory response
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9138455B2
(en)
|
2013-03-15 |
2015-09-22 |
Mead Johnson Nutrition Company |
Activating adiponectin by casein hydrolysate
|
|
WO2014144325A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Methods and compositions for improving detection and/or capture of a target entity
|
|
US9345727B2
(en)
|
2013-03-15 |
2016-05-24 |
Mead Johnson Nutrition Company |
Nutritional compositions containing a peptide component and uses thereof
|
|
US9345741B2
(en)
|
2013-03-15 |
2016-05-24 |
Mead Johnson Nutrition Company |
Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US8889633B2
(en)
|
2013-03-15 |
2014-11-18 |
Mead Johnson Nutrition Company |
Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US9289461B2
(en)
|
2013-03-15 |
2016-03-22 |
Mead Johnson Nutrition Company |
Reducing the risk of autoimmune disease
|
|
CN105246914B
(zh)
|
2013-04-02 |
2021-08-27 |
中外制药株式会社 |
Fc区变体
|
|
JP6649250B2
(ja)
*
|
2013-05-21 |
2020-02-19 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
操作されたヘム結合性構成物およびその使用
|
|
KR101654890B1
(ko)
*
|
2013-07-10 |
2016-09-07 |
한국과학기술원 |
면역글로불린 g에 대한 리피바디 및 그 용도
|
|
FR3012453B1
(fr)
|
2013-10-31 |
2015-11-13 |
Lab Francais Du Fractionnement |
Proteine chimerique dans le traitement de l’amylose
|
|
EP3077504B1
(en)
|
2013-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
|
US10513546B2
(en)
|
2013-12-18 |
2019-12-24 |
President And Fellows Of Harvard College |
CRP capture/detection of gram positive bacteria
|
|
SG11201605203UA
(en)
|
2013-12-24 |
2016-07-28 |
Argen X N V |
Fcrn antagonists and methods of use
|
|
MX2016008498A
(es)
|
2013-12-27 |
2016-10-07 |
Chugai Pharmaceutical Co Ltd |
Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
|
|
LT3099713T
(lt)
*
|
2014-02-02 |
2020-07-10 |
Medimmune Limited |
Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno
|
|
MX2016010951A
(es)
|
2014-03-05 |
2016-11-29 |
Ucb Biopharma Sprl |
Proteinas de fc multimericas.
|
|
CA2939006A1
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
AU2015237864B2
(en)
*
|
2014-03-24 |
2020-12-03 |
Cancer Research Technology Limited |
Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
|
|
EP3699195A3
(en)
|
2014-03-28 |
2020-11-04 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
EP4299595A3
(en)
|
2014-05-02 |
2024-03-13 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
|
EP3148573A4
(en)
*
|
2014-05-29 |
2017-11-15 |
Medimmune, LLC |
Ox40l fusion proteins and uses thereof
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
|
EP3169363A4
(en)
*
|
2014-07-16 |
2018-02-21 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
US10655124B2
(en)
*
|
2014-10-20 |
2020-05-19 |
The Scripps Research Institute |
Proximity based methods for selection of binding partners
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
|
CN104403004B
(zh)
*
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
MX389350B
(es)
|
2014-12-05 |
2025-03-19 |
Alexion Pharma Inc |
Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US9767555B2
(en)
*
|
2015-01-05 |
2017-09-19 |
Case Western Reserve University |
Disease characterization from fused pathology and radiology data
|
|
JP6868561B2
(ja)
|
2015-01-28 |
2021-05-12 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
アルカリホスファターゼ欠損を有する被験者を治療する方法
|
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
CA2978253A1
(en)
|
2015-03-09 |
2016-09-15 |
Argenx Bvba |
Methods of reducing serum levels of fc-containing agents using fcrn antagonists
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
CN107750255B
(zh)
|
2015-04-17 |
2022-08-30 |
安进研发（慕尼黑）股份有限公司 |
用于cdh3和cd3的双特异性抗体构建体
|
|
ES2983120T3
(es)
*
|
2015-06-12 |
2024-10-21 |
Ubi Pharma Inc |
Proteínas de fusión de inmunoglobulinas y usos de las mismas
|
|
WO2016207402A1
(en)
|
2015-06-26 |
2016-12-29 |
Institute For Research In Biomedicine |
Proteins comprising a mutated lair-1 fragment and uses thereof
|
|
KR20250053203A
(ko)
|
2015-07-24 |
2025-04-21 |
글리크닉 인코포레이티드 |
향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
|
|
EA039859B1
(ru)
*
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
*
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EP3331549B1
(en)
|
2015-08-06 |
2020-12-23 |
President and Fellows of Harvard College |
Improved microbe-binding molecules and uses thereof
|
|
US11254744B2
(en)
|
2015-08-07 |
2022-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
CN108350440A
(zh)
|
2015-08-17 |
2018-07-31 |
阿雷克森制药公司 |
碱性磷酸酯的制造
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
AU2016325630B2
(en)
|
2015-09-23 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-CD3 bispecific antibodies and uses thereof
|
|
JP6868617B2
(ja)
|
2015-09-28 |
2021-05-12 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
|
|
WO2017059878A1
(en)
|
2015-10-07 |
2017-04-13 |
Humabs Biomed Sa |
Antibodies that potently neutralize hepatitis b virus and uses thereof
|
|
JP2018533571A
(ja)
|
2015-10-30 |
2018-11-15 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
患者の頭蓋縫合早期癒合症を治療するための方法
|
|
KR20180083874A
(ko)
*
|
2015-11-04 |
2018-07-23 |
사울 제이. 프라이스맨 |
Her2를 표적화하는 키메라 항원 수용체
|
|
EP3374390A1
(en)
|
2015-11-13 |
2018-09-19 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
EP3384029B1
(en)
*
|
2015-12-03 |
2022-01-05 |
National Health Research Institutes |
Heterodimeric vascular endothelial growth factor and use thereof
|
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
CA3012695A1
(en)
|
2016-02-01 |
2017-08-10 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
EA201891753A1
(ru)
*
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
|
AU2017222564A1
(en)
|
2016-02-24 |
2018-09-06 |
Visterra, Inc. |
Formulations of antibody molecules to influenza virus
|
|
EP3423572B1
(en)
|
2016-03-02 |
2023-11-29 |
Momenta Pharmaceuticals, Inc. |
Methods related to engineered fc constructs
|
|
WO2017155569A1
(en)
|
2016-03-08 |
2017-09-14 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
|
AU2017245143B2
(en)
|
2016-03-30 |
2024-01-11 |
Ab Biosciences, Inc. |
Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
|
|
US10898549B2
(en)
|
2016-04-01 |
2021-01-26 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
JP7613826B2
(ja)
|
2016-04-01 |
2025-01-15 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
アルカリホスファターゼによって筋力低下を治療すること
|
|
US10723857B1
(en)
*
|
2016-04-15 |
2020-07-28 |
United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration |
Polyimide aerogels with reduced shrinkage from isothermal aging
|
|
KR101685532B1
(ko)
*
|
2016-04-26 |
2016-12-13 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질
|
|
DK3484514T3
(da)
|
2016-05-23 |
2024-01-29 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
US10988744B2
(en)
|
2016-06-06 |
2021-04-27 |
Alexion Pharmaceuticals, Inc. |
Method of producing alkaline phosphatase
|
|
AU2017279538A1
(en)
|
2016-06-07 |
2019-01-03 |
Gliknik Inc. |
Cysteine-optimized stradomers
|
|
JP7010854B2
(ja)
|
2016-06-14 |
2022-01-26 |
ゼンコア インコーポレイテッド |
二重特異性チェックポイント阻害剤抗体
|
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
WO2018010789A1
(en)
*
|
2016-07-13 |
2018-01-18 |
Humabs Biomed Sa |
Novel antibodies specifically binding to zika virus epitopes and uses thereof
|
|
CN106191072A
(zh)
*
|
2016-08-04 |
2016-12-07 |
沈沭彤 |
重组人源嵌合GcFc基因片段及融合蛋白
|
|
EP3500289B1
(en)
|
2016-08-18 |
2024-10-09 |
Alexion Pharmaceuticals, Inc. |
Asfotase alfa for use in treating tracheobronchomalacia
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
CN110022898B
(zh)
|
2016-12-09 |
2023-07-04 |
格利克尼克股份有限公司 |
用多价Fc化合物治疗炎性疾病的方法
|
|
MX2019006573A
(es)
|
2016-12-09 |
2019-11-18 |
Gliknik Inc |
Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
|
|
US20200031895A1
(en)
|
2016-12-16 |
2020-01-30 |
Biogen Ma Inc. |
Stabilized proteolytically activated growth differentiation factor 11
|
|
JP7146771B2
(ja)
|
2017-01-06 |
2022-10-04 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
操作されたＦｃコンストラクトに関する組成物及び方法
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, LLC |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
CN110944661A
(zh)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
|
EP3600383A4
(en)
|
2017-03-31 |
2020-10-28 |
Alexion Pharmaceuticals, Inc. |
METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
|
|
WO2018193063A2
(en)
|
2017-04-19 |
2018-10-25 |
Institute For Research In Biomedicine |
Novel malaria vaccines and antibodies binding to plasmodium sporozoites
|
|
KR102840867B1
(ko)
|
2017-05-24 |
2025-07-30 |
에이엘에스 테라피 디벨럽먼트 인스티튜트 |
치료용 항-cd40 리간드 항체
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
WO2019024979A1
(en)
|
2017-07-31 |
2019-02-07 |
Institute For Research In Biomedicine |
FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
|
|
NZ762100A
(en)
|
2017-08-09 |
2025-12-19 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
|
US12297272B2
(en)
*
|
2017-08-15 |
2025-05-13 |
Eianco US inc. |
IgG Fc variants for veterinary use
|
|
EP3668893A4
(en)
*
|
2017-08-16 |
2021-08-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
|
|
CA3073537A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
|
WO2019042555A1
(en)
|
2017-08-31 |
2019-03-07 |
Humabs Biomed Sa |
MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
CA3081144A1
(en)
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
AU2018387829B2
(en)
|
2017-12-22 |
2024-12-19 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
AU2019215063B2
(en)
|
2018-02-01 |
2025-10-16 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing Factor VIII
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
CA3237846A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
US11913039B2
(en)
|
2018-03-30 |
2024-02-27 |
Alexion Pharmaceuticals, Inc. |
Method for producing recombinant alkaline phosphatase
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
CN119080931A
(zh)
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
EP3802619A1
(en)
|
2018-06-08 |
2021-04-14 |
F. Hoffmann-La Roche AG |
Peptidic linker with reduced post-translational modification
|
|
US12202900B2
(en)
|
2018-06-08 |
2025-01-21 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
EP3833766A1
(en)
|
2018-08-09 |
2021-06-16 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
US12268733B2
(en)
|
2018-08-10 |
2025-04-08 |
Alexion Pharmaceuticals, Inc. |
Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
|
|
CA3110513A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
|
BR112021004266A2
(pt)
|
2018-09-06 |
2021-08-03 |
Cidara Therapeutics, Inc. |
conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
JP7644007B2
(ja)
|
2018-12-06 |
2025-03-11 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｉｘ因子を発現するレンチウイルスベクターの使用
|
|
FI3898668T3
(fi)
|
2018-12-19 |
2023-11-28 |
Humabs Biomed Sa |
B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
|
|
RS67553B1
(sr)
|
2018-12-20 |
2026-01-30 |
Humabs Biomed Sa |
Kombinovana hbv terapija
|
|
CA3129501A1
(en)
*
|
2019-02-15 |
2020-08-20 |
University Of Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
US11230593B2
(en)
|
2019-03-25 |
2022-01-25 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
SG11202111290WA
(en)
|
2019-04-17 |
2021-11-29 |
Codiak Biosciences Inc |
Compositions of exosomes and aav
|
|
WO2020221451A1
(en)
|
2019-04-30 |
2020-11-05 |
Humabs Biomed Sa |
Antibodies binding to plasmodium circumsporozoite protein and uses thereof
|
|
JP7565951B2
(ja)
|
2019-06-07 |
2024-10-11 |
アルジェニクス ビーブイ |
皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
|
|
EP3757127A1
(en)
|
2019-06-28 |
2020-12-30 |
Institute for Research in Biomedicine |
Deimmunized antibodies binding to alpha-4 integrin and uses thereof
|
|
US20220267467A1
(en)
*
|
2019-07-19 |
2022-08-25 |
WuXi Biologics Ireland Limited |
Polypeptide complex for conjugation and use thereof
|
|
CN114599389A
(zh)
*
|
2019-08-22 |
2022-06-07 |
奇达拉治疗公司 |
变体fc结构域及其用途
|
|
CA3152511A1
(en)
|
2019-08-29 |
2021-03-04 |
Vir Biotechnology, Inc. |
Antibody compositions and methods for treating hepatitis b virus infection
|
|
TWI861205B
(zh)
|
2019-09-06 |
2024-11-11 |
美商席達拉醫療有限公司 |
用於治療病毒感染之組合物及方法
|
|
CN114929750B
(zh)
|
2019-09-13 |
2024-11-22 |
芝加哥大学 |
用于治疗葡萄球菌感染的方法和组合物
|
|
KR20220097891A
(ko)
|
2019-09-30 |
2022-07-08 |
바이오버라티브 테라퓨틱스 인크. |
렌티바이러스 벡터 제형
|
|
TW202136300A
(zh)
*
|
2019-11-06 |
2021-10-01 |
德商安美基研究（慕尼黑）公司 |
用於在增殖性疾病中使用的多靶向抗原結合分子
|
|
CA3161266A1
(en)
|
2019-12-09 |
2021-06-17 |
Alexion Pharmaceuticals, Inc. |
Alkaline phosphatase polypeptides and methods of use thereof
|
|
WO2021119467A1
(en)
|
2019-12-11 |
2021-06-17 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
JP2023509195A
(ja)
|
2020-01-08 |
2023-03-07 |
アルジェニクス ビーブイ |
天疱瘡症を治療する方法
|
|
JP7512394B2
(ja)
|
2020-05-06 |
2024-07-08 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
PH12022553569A1
(en)
|
2020-06-24 |
2023-04-12 |
Humabs Biomed Sa |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
|
MX2023000156A
(es)
|
2020-06-24 |
2023-02-16 |
Bioverativ Therapeutics Inc |
Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
|
|
AU2021337652B2
(en)
|
2020-09-04 |
2025-01-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treating bone mineralization disorders
|
|
CA3196766A1
(en)
|
2020-11-02 |
2022-05-05 |
Attralus, Inc. |
Sap fc fusion proteins and methods of use
|
|
WO2022122704A1
(en)
|
2020-12-08 |
2022-06-16 |
Humabs Biomed Sa |
Antibodies binding to f-protein of metapneumovirus and uses thereof
|
|
WO2022122788A1
(en)
|
2020-12-09 |
2022-06-16 |
Institute For Research In Biomedicine |
Multispecific antibodies against severe acute respiratory syndrome coronavirus 2
|
|
JP2024504167A
(ja)
|
2021-01-26 |
2024-01-30 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
|
|
WO2022162012A2
(en)
|
2021-01-26 |
2022-08-04 |
Eth Zurich |
Antibodies broadly targeting coronaviruses and uses thereof
|
|
WO2022161598A1
(en)
|
2021-01-26 |
2022-08-04 |
Eth Zurich |
Antibodies broadly targeting coronaviruses and uses thereof
|
|
BR112023016048A2
(pt)
|
2021-02-12 |
2023-11-14 |
Alexion Pharma Inc |
Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
JP2024509973A
(ja)
|
2021-03-10 |
2024-03-05 |
マビュロン アーゲー |
Ｔｄｐ－４３に対する抗体およびその使用方法
|
|
CN113234168B
(zh)
*
|
2021-06-04 |
2022-09-13 |
浙江大学 |
一种融合蛋白、基因及应用
|
|
CN113406320B
(zh)
*
|
2021-08-18 |
2021-11-02 |
南京立顶医疗科技有限公司 |
基于重组基因工程抗体和微球的定向偶联方法及应用
|
|
CN118139879A
(zh)
|
2021-09-07 |
2024-06-04 |
生物医学研究院 |
结合破伤风毒素的抗体及其用途
|
|
KR20240067088A
(ko)
*
|
2021-09-16 |
2024-05-16 |
지티 바이오파마, 인크. |
융합 단백질을 표적으로 하는 pd-l1 및 이의 사용 방법
|
|
KR20240134900A
(ko)
|
2022-01-17 |
2024-09-10 |
아르젠엑스 비브이 |
자가항체 매개 질환 환자를 치료하기 위한 방법
|
|
MX2024010165A
(es)
|
2022-02-21 |
2024-08-27 |
argenx BV |
Metodos para tratar la miositis mediante el uso de antagonistas de fcrn.
|
|
WO2023213400A1
(en)
|
2022-05-05 |
2023-11-09 |
Institute For Research In Biomedicine |
Antibodies against chemokines, method for identifying said antibodies and uses thereof
|
|
WO2023222214A1
(en)
|
2022-05-18 |
2023-11-23 |
Mabylon Ag |
Anti-allergen antibodies and uses thereof
|
|
CN119698429A
(zh)
|
2022-06-15 |
2025-03-25 |
阿根思有限公司 |
Fcrn结合分子及使用方法
|
|
AR130995A1
(es)
|
2022-11-07 |
2025-02-05 |
argenx BV |
Métodos para el tratamiento de nefropatías membranosas primarias mediante el uso de antagonistas de fcrn
|
|
WO2024114906A1
(en)
|
2022-11-30 |
2024-06-06 |
Mabylon Ag |
Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
|
|
EP4630444A1
(en)
|
2022-12-08 |
2025-10-15 |
CSL Behring LLC |
Dissociable envelope binding proteins and uses thereof
|
|
AR131560A1
(es)
|
2023-01-06 |
2025-04-09 |
argenx BV |
Métodos para tratar pots mediante el uso de antagonistas de fcrn
|
|
CN120659623A
(zh)
|
2023-01-12 |
2025-09-16 |
阿根思有限公司 |
用于使用fcrn拮抗剂治疗原发性干燥综合征的方法
|
|
WO2024189430A1
(en)
|
2023-03-14 |
2024-09-19 |
argenx BV |
Methods for vaccination of a subject treated with an fcrn antagonist
|
|
WO2024251358A1
(en)
|
2023-06-07 |
2024-12-12 |
Mabylon Ag |
Anti-allergen antibodies and uses thereof
|
|
IL325970A
(en)
|
2023-07-16 |
2026-03-01 |
argenx BV |
Methods for treating chronic inflammatory demyelinating neuropathy
|
|
WO2025035176A1
(en)
*
|
2023-08-14 |
2025-02-20 |
The Bionics Institute Of Australia |
A fusion protein
|
|
US20250101111A1
(en)
|
2023-09-07 |
2025-03-27 |
argenx BV |
Fcrn antagonists and methods of use
|
|
WO2025109206A1
(en)
|
2023-11-22 |
2025-05-30 |
Mabylon Ag |
Multispecific anti-allergen antibodies and uses thereof
|
|
WO2025108551A1
(en)
|
2023-11-23 |
2025-05-30 |
Mabylon Ag |
Multispecific anti-allergen antibodies and uses thereof
|
|
GB202318512D0
(en)
|
2023-12-04 |
2024-01-17 |
argenx BV |
Methods of determining potency
|
|
WO2025133694A1
(en)
|
2023-12-20 |
2025-06-26 |
argenx BV |
Fcrn/hsa-binding molecules and methods of use
|
|
US20260035414A1
(en)
*
|
2024-08-01 |
2026-02-05 |
Twilight Bioscience, Inc. |
Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use
|